P
CORT icon

&Partners’s Corcept Therapeutics CORT Stock Holding History

&Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438K Buy
+5,027
New +$304K ﹤0.01% 1918
2025
Q4 		– Sell
-5,526
Closed -$459K – 2296
2025
Q3 		$459K Buy
5,526
+937
+20% +$67.8K ﹤0.01% 1506
2025
Q2 		$339K Sell
4,589
-1,596
-26% -$116K ﹤0.01% 1564
2025
Q1 		$338K Sell
6,185
-840
-12% -$51.1K ﹤0.01% 1342
2024
Q4 		$361K Sell
7,025
-369
-5% -$19.3K ﹤0.01% 1236
2024
Q3 		$280K Buy
+7,394
New +$263K 0.01% 1134

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

&Partners's CORT Position: Q2 2026 in Review

&Partners opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 5,027 shares worth $438K. The stake represents ﹤0.01% of the portfolio and ranks #1918 among its holdings. This is a return to the name: &Partners previously reported a position in CORT as recently as Q3 2025.

&Partners first reported a position in CORT in Q3 2024 and has held it in 6 quarters since. The position peaked at $459K in Q3 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • &Partners held 5,027 shares of Corcept Therapeutics worth $438K as of Q2 2026.
  • Corcept Therapeutics was a new &Partners position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #1918 holding.
  • &Partners first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • &Partners's Corcept Therapeutics position peaked at $459K in Q3 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.